Amelioration of rat antigen-induced arthritis by liposomally conjugated methotrexate is accompanied by down-regulation of cytokine mRNA expression

Citation
As. Williams et al., Amelioration of rat antigen-induced arthritis by liposomally conjugated methotrexate is accompanied by down-regulation of cytokine mRNA expression, RHEUMATOLOG, 40(4), 2001, pp. 375-383
Citations number
24
Categorie Soggetti
Rheumatology
Journal title
RHEUMATOLOGY
ISSN journal
14620324 → ACNP
Volume
40
Issue
4
Year of publication
2001
Pages
375 - 383
Database
ISI
SICI code
1462-0324(200104)40:4<375:AORAAB>2.0.ZU;2-5
Abstract
Objectives. We examined the temporal changes in the expression of interleuk in 1 beta (IL-1 beta). tumour necrosis factor alpha (TNF-alpha) and interle ukin 6 (IL-6) in the rat antigen-induced arthritis (AIA) model and investig ated how their expression was modulated following disease amelioration by l iposomally conjugated methotrexate (G-MLV). Methods. On the day of arthritis induction (day 0), rats were treated with a single intraarticular injection of G-MLV, methotrexate (MTX). a dose of l ipid equivalent to G-MLV (E-LIPO) or saline. On days 3 and 7 after disease induction, animals from each experimental group were killed. Joint tissue w as examined histologically and for mRNA expression (IL-6, IL-1 beta and TNF -alpha) using semiquantitative reverse transcription-polymerase chain react ion. Results. There was no significant difference (ANOVA) in knee swelling betwe en MTX-, E-MLV- or saline-treated animals from day 0 to day 7. By day 1, G- MLV significantly reduced knee swelling (1.94 +/- 0.12 mm; P < 0.0001) comp ared with rats treated with MTX (3.17 +/- 0.18 mm). G-MLV treatment also si gnificantly inhibited the histological progression of AIA. This reduction i n disease severity was accompanied by a reduction in IL-1 beta mRNA express ion in synovial tissue extracts on day 3 and IL-6 mRNA expression on both d ay 3 and day 7. Conclusions. Liposomally conjugated MTX may exert its beneficial effects in experimental arthritis through IL-1 beta and IL-6 inhibition.